Host defence against disseminated Candida albicans infection and implications for antifungal immunotherapy.
SourceExpert Opinion on Biological Therapy, 6, 9, (2006), pp. 891-903
Article / Letter to editor
Display more detailsDisplay less details
Expert Opinion on Biological Therapy
SubjectEBP 3: Effective Primary Care and Public Health; N4i 1: Pathogenesis and modulation of inflammation; N4i 2: Invasive mycoses and compromised host; NCMLS 1: Infection and autoimmunity; UMCN 4.1: Microbial pathogenesis and host defense
The different manifestations of Candida albicans infection are dictated by an underlying defect in the immune response of the host. Protective immunity to disseminated candidiasis, the manifestation of C. albicans infection discussed in this review, has traditionally been ascribed to innate immunity with emphasis on the role of granulocytes. Lately, however, immunological studies have learned that host defence against disseminated candidiasis is based on a complex interplay between innate and cell-mediated immunity. Despite the availability of new antifungal agents, mortality associated with disseminated C. albicans infection remains high. Immunotherapy that augments host defence is an important strategic option in the battle against disseminated candidiasis. Here, the authors review the chronological events in the pathogenesis of disseminated candidiasis that aid in predicting the impact of existing immunotherapy and the development of future immunomodulating strategies.
Upload full text